German Forest Air Flies Around the World

(openPR) The biotech start-up Airnergy International GmbH from Germany was the first to develop a medical technology which follows an example set by nature and converts oxygen into a state the human body is better able to metabolise and regenerate. Sunlight and chlorophyll of plants, i.e. photosynthesis, serve as example for this natural remedy. In the so-called Spirovital-Therapy, neither the volume of oxygen is increased nor oxygen ionised or ozone added.

Studies have substantiated the medical-scientific effects of the Spirovitalisation method and it has been certified as a medical product in Europe, Russia, Mexico and the USA. Authorization by the Chinese SFDA is expected to be granted in 2012.

Worldwide about 100,000 of these patented catalysts which energize respiratory oxygen are in use. Airnergy can be used in the medical or commercial sectors, for wellness and fitness, in a company or at home. Depending on the area of usage, the number of catalysts varies: The more catalysts used, the more quickly positive effects are experienced and the stronger these effects are.

This revolutionary energy therapy has its origin about 20 years ago. After the catastrophe in Tschernobyl, a study conducted among 1,000 affected children aroused interest as those treated with Spirovitalisation experienced an enormous improvement in health, in contrast to those treated with conventional methods. Today, worldwide, millions of these treatments are in effect and world class athletes, Hollywood stars and managers, as well as thousands of doctors and patients and families use the Spirovitalisation.

The current head of Airnergy's scientific council, Prof. Jung, led the department for Sports Medicine, Rehabilitation and Prevention at Johannes-Gutenberg-University in Mainz, Germany for 25 years.

His own scientific results and personal experience make him confident that this method has the potential to become a common, public therapy worldwide. (http://www.schlafstoerungen-online.de/component/content/article/164.html)